Now, single tablet to protect your pet against 6 parasites

Staff ReporterJanuary 27, 202538 min

Elanco Animal Health, Inc., has announced the market availability of Credelio Quattro, a broad spectrum chewable anti-parasite tablet with four established and powerful ingredients. The tablet, which contains lotilaner, moxidectin, praziquantel, and pyrantel, is designed to deliver the broadest protection against parasites—based on label comparison of the number of parasite types covered in a chewable that targets ticks—the company said in a press release.

Credelio Quattro is the first and only monthly chewable tablet of its kind to protect against six different types of parasites, including three risky intestinal worms that can be passed to humans, the company said. These are: tapeworms, roundworms, hookworms (Uncinaria stenocephala), heartworms, ticks, and fleas. The company had announced on October 7 the U.S. Food and Drug Administration’s approval for use of the tablet.

“Today is a historic day as we bring veterinarians and pet owners peace of mind with the broadest parasite protection of its kind for dogs,” said Bobby Modi, Elanco Animal Health’s executive vice-president for U.S. pet health and global digital transformation.

Also Read: College of Veterinary Medicine dean says best time to be a veterinarian

Modi said the company’s research had shown that 94% of dog owners see proactive treatment for intestinal worms, including tapeworms, as a priority. “And when looking for intestinal worm protection for their dog, owners care most about product effectiveness, parasite coverage, and duration of protection,” he said.

By providing the broadest range of parasite protection, covering six parasites in a single, chewable tablet, Credelio Quattro delivers on these expectations, Modi said, strengthening Elanco’s market presence and positioning it for continued growth in the parasiticide segment.

Also Read: Feeding your pet raw food may not be such a great idea

The broad range of parasite protection from Credelio Quattro in a single, chewable monthly tablet makes it easier for pet owners to protect against some of the more common and challenging parasites, Elanco Animal Health said. Citing a comparative study—Reif K.E., Kollasch T.M., Neilson J.C., Herrin B.H., Ryan W.G., Bell M.C., Beltz M.S., Dryden M.W., Jesudoss Chelladurai J.R.J., Miller K.R., Sutherland C.J. Comparative speed of kill provided by lotilaner (Credelio), sarolaner (Simparica Trio), and afoxolaner (NexGard) to control Amblyomma americanum infestations on dogs. Parasite Vectors. 2024 Jul 20;17(1):313.—the company said Credelio Quattro has been shown to be 100% efficacious against tapeworms (Echinococcus granulosus, Dipylidium caninum, and Taenia pisiformis) with its industry-established dose of praziquantel, one of the active ingredients in Credelio Quattro. The chewable tablet also contains lotilaner, which kills ticks (Amblyomma americanum or lone star tick) twice as fast as sarolaner in Simparica Trio, a registered trademark of Zoetis Services LLC, and afoxolaner in NexGard, a registered trademark of Boehringer Ingelheim Animal Health USA, Inc. The company made this claim on the basis of the time to statistical significance versus control in a single study on Day 21 and Day 28 for reinfestations. The study compared Credelio (lotilaner)—not Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard (afoxolaner).

Also Read: New diagnostic panel helps detect canine lymphoma early

The company said its research also showed an important gap where pet owners need to lean in to better protect their pets against risky parasites. Just one in three respondents believed fleas and ticks are a year-round risk; and only half of dog owners surveyed protect against heartworm disease throughout the year, as per Elanco Animal Health data from February. With the geographic spread of parasites and increasing disease pressure, the importance of year-round protection is more significant than ever, the company said in its release.

“Parasites like tapeworms, fleas, and ticks can carry dangerous diseases and some of these can spread from dogs to humans,” said Dr Casey Locklear, veterinarian and parasiticide lead for Elanco Animal Health. “The Companion Animal Parasite Council recommends year-round prevention of parasites, even during the winter months, and specifically mentions the need for monthly deworming of dogs with praziquantel in areas where a certain type of tapeworm —E. granulosus—are endemic.”

Veterinarians in North America can place their orders at CredelioQuattroVet.com. The medication makes its debut at the Veterinary Meeting & Expo currently on in Orlando, Florida, from Saturday through Wednesday.

Also Read: New stairs promise to make road travel safer for your dog

Elanco Animal Health, based in Greenfield, Indiana, is a global leader in animal health with a history of 70 years dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole.

Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies eight weeks of age or older and weighing at least 3.3 pounds, or 1.5 kg.

WARNING: Lotilaner, an ingredient in Credelio Quattro, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, ataxia, and seizures even in dogs without a history of seizures. The company has advised using with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before administering Credelio Quattro as it is not effective against adult D. immitis. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhoea.

SOURCE: PR Newswire

Caution: Information in news reports, press releases, or articles on TheSnout.in is not intended to serve as a medical opinion or advice. Do not attempt to treat yourself or your pets without consulting the appropriate medical professional.

Staff Reporter

Leave a Reply

Your email address will not be published. Required fields are marked *